A study from Watson School of Biological Sciences shows that SRSF1 is a critical transcriptional target of c-MYC. This study was published in the Feb 20, 2012 Cell Rep by Prof. Dr Krainer AR & Das, Watson School of Biological Sciences, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for human cancers: Endothelin-1 suppresses the expression of SRSF1 via up regulation of its target gene. This data suggest that Endothelin-1, by suppressing the expression of SRSF1, it will decrease the expression of a number of oncogenic mRNAs in cancer cells.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for human cancers: Endothelin-1 suppresses the expression of SRSF1 via up regulation of its target gene, 20/June/2014, 8.34 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
*Research cooperation
